Gubra A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GUBRA.CO research report →
About the company
Gubra A/S is a biotechnology firm engaged in two core activities: offering contract research organization (CRO) services for pre-clinical development, and advancing its own internal early-stage drug and target discovery initiatives. Its CRO division provides specialized pre-clinical research and development support to companies in the pharmaceutical and biotechnology sectors. These services encompass a wide range of capabilities, including in vivo pharmacology, tissue analysis, various assay development, molecular pharmacology, bioanalytical testing, next-generation sequencing (NGS), and both two-dimensional and three-dimensional imaging techniques.
- CEO
- Markus Rohrwild
- IPO
- 2023
- Employees
- 260
- HQ
- Horsholm, DK
Price Chart
- Market Cap
- $5.49B
- P/E
- 3.24
- P/S
- 2.08
- P/B
- 4.79
- EV/EBITDA
- 2.58
- Div Yield
- 18.21%
- Gross Margin
- 96.96%
- Op Margin
- 81.66%
- Net Margin
- 64.11%
- ROE
- 143.20%
- ROIC
- 134.80%
- Revenue
- $2.64B · 892.25%
- Net Income
- $1.69B · 4731.94%
- EPS
- $103.83 · 4735.27%
- Op Income
- $2.22B
- FCF YoY
- 6355.26%
- 52W High
- $557.50
- 52W Low
- $293.00
- 50D MA
- $337.86
- 200D MA
- $406.30
- Beta
- 0.27
- Avg Volume
- 31.68K
Get TickerSpark's AI analysis on GUBRA.CO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our GUBRA.CO coverage
Recent articles, reports, and earnings notes.
No research on GUBRA.CO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GUBRA.CO report →Similar companies
Peers in the same neighborhood.